Skip to main content
SpringerLink
Log in

Approach to the patient with recurrent neprolithiasis

  • Nephrolithiasis
  • Published:
Clinical Reviews in Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Although recurring nephrolithiasis may not be as common as single-episode disease, it poses greater problems to the patient's daily lifestyle and general future health status. The general need for an adequate history, examination, and radiological assessment is acknowledged, but a more intensive investigative and management approach is required. Investigations for secondary causes are paramount and may lead to identification of unusual metabolic abnormalities and specific therapies. Such medical approaches entail consideration of dietary adjustments to lower the urinary excretion of components of the renal stones, pharmacological therapies to modulate urinary constituents and limit renal stone risk, and monitoring efficacy of the therapy over time. This approach will prevent significant deterioration of renal function and other serious metabolic consequences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bihl G, Meyers A. 2001 Recurrent renal stone disease-advances in patho genesis and clinical management. Lancet 358:651–656.

    Article  PubMed  CAS  Google Scholar 

  2. Gambaro G, Favaro S, D'Angelo A. 2001 Risk for renal failure in nephrolithiasis. Am J Kidney Dis 37:233–243.

    Article  PubMed  CAS  Google Scholar 

  3. Parks JH, Coe FL. 1996 The financial effects of kidney stone prevention. Kidney Int 50:1706–1712.

    Article  PubMed  CAS  Google Scholar 

  4. Pak CYC, Resnick MI. 2000 Medical therapy and new approaches to management of urolithiasis. Urol Clin North Am 27:243–253.

    Article  PubMed  CAS  Google Scholar 

  5. Levy FL, Adams-Huet B, Pak CYC. 1995 Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 98:50–59.

    Article  PubMed  CAS  Google Scholar 

  6. Trinchieri A, Ostini F, Nespoli R, Rovera F, Montanari E, Zametti G. 1999 A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol 162:27–30.

    Article  PubMed  CAS  Google Scholar 

  7. Ettinger B. 1979 Recurrence of nephrolithiasis. Am J Med 67:245–248.

    Article  PubMed  CAS  Google Scholar 

  8. Ljunghall S, Lithell H, Skarfors E. 1987 Prevalence of renal stones in 60-year-old men. Br J Urol 60:10–13.

    PubMed  CAS  Google Scholar 

  9. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. 1997 Family history and risk of kidney stones. J Am Soc Nephrol 8:1568–1573.

    PubMed  CAS  Google Scholar 

  10. Parks JH, Coe FL. 1994 An increasing number of calcium oxalate stone events worsens treatment outcome. Kidney Int 45:1722–1730.

    Article  PubMed  CAS  Google Scholar 

  11. Matlaga BR, Assimos DG. 2003 Urologic manifestations of nonurologic disease: Urolithiasis. Urol Clin North Am 30:91–99.

    Article  PubMed  Google Scholar 

  12. Maalouf N, Pak CYC: Nephrolithiasis, in Clinical Nephrology, Dialysis, and Transplantation, Malluche HH, Sawaya BP, Hakim RM, Sayegh MH, eds, Dustri-Verlag, Rockledge, FL.

  13. Moe OW, Abate N, Sakhaee K. 2002 Pathophysiology of uric acid nephrolithiasis. Endocrinol Metab Clin N Am 31:895–914.

    Article  CAS  Google Scholar 

  14. Abate N, Chandalia M, Cabo-Chan AV, Moe OW, Sakhaee K. 2004 The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65:386–392.

    Article  PubMed  CAS  Google Scholar 

  15. Leusmann DB, Niggemann H, Roth S, von Ahlen H. 1995 Recurrence rates and severity of urinary calculi. Scand J Urol Nephrol 29:279–283.

    PubMed  CAS  Google Scholar 

  16. Pak CYC, Skurla C, Harvey J. 1985 Graphic display of urinary risk factors for renal stone formation. J Urol 134:867–870.

    PubMed  CAS  Google Scholar 

  17. Pak CY. 1982 Should patients with single renal stone occurrence undergo diagnostic evaluation. J Urol 127:855–858.

    PubMed  CAS  Google Scholar 

  18. Yagisawa T, Chandhoke PS, Fan J. 1998 Metabolic risk factors in patients with first-time and recurrent stone formations as determined by comprehensive metabolic evaluation. Urology 52:750–755.

    Article  PubMed  CAS  Google Scholar 

  19. Strauss AL, Coe FL, Deutsch L, Parks JH. 1982 Factors that predict relapse of calcium nephrolithiasis during treatment. Am J Med 72:17–24.

    Article  PubMed  CAS  Google Scholar 

  20. Coe FL, Keck J, Norton ER. 1977 The natural history of calcium urolithiasis. JAMA 238:1519–1523.

    Article  PubMed  CAS  Google Scholar 

  21. Pak CYC. 1997 Medical management of nephrolithiasis—A new simplified approach for general practice. Am J Med Sci 313:215–219.

    Article  PubMed  CAS  Google Scholar 

  22. Pak CYC, Asplin JR, Ogawa Y, Resnick MI, Rodgers AL, Traxer O. 2001 Evaluation of stone-forming patients. Paris Consultation on Stone Disease. Paris, France

  23. Pak CY, Kaplan R, Bone H, Townsend J, Waters O. 1975 A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. New Engl J Med 292:497–500.

    Article  PubMed  CAS  Google Scholar 

  24. Pak CYC, Ohata M, Lawrence EC, Snyder W. 1974 The hypercalciurias: causes, parathyroid functions, and diagnostic criteria. J Clin Invest 54:387–400.

    Article  PubMed  CAS  Google Scholar 

  25. Lawoyin S, Sismilich S, Browne R, Pak CY. 1979 Bone mineral content in patients with calcium urolithiasis. Metabolism 28:1250–1254.

    Article  PubMed  CAS  Google Scholar 

  26. Pietschmann F, Breslau NA, Pak CYC. 1992 Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 7:1383–1388.

    Article  PubMed  CAS  Google Scholar 

  27. Reed BY, Gitomer WL, Heller HJ, et al. 2002 Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab 87:1476–1485.

    Article  PubMed  CAS  Google Scholar 

  28. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. 1996 Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 155:839–843.

    Article  PubMed  CAS  Google Scholar 

  29. Borghi L, Schianchi T, Meschi T, et al. 2002 Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. New Engl J Med 346:77–84.

    Article  PubMed  CAS  Google Scholar 

  30. Wabner CL, Pak CYC. 1993 Effect of orange juice consumption on urinary stone risk factors. J Urol 149:1405–1408.

    PubMed  CAS  Google Scholar 

  31. Insogna KL, Ellison AS, Burtis WJ, Sartori L, Lang RL, Broadus AE. 1989 Trichlormethizide and oral phosphate therapy in patients with absorptive hypercalciuria. J Urol 141:269–274.

    PubMed  CAS  Google Scholar 

  32. Ettinger B, Citron JT, Livermore B, Dolman LI. 1988 Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139:679–684.

    PubMed  CAS  Google Scholar 

  33. Pearle MS, Roehrborn CG, Pak CYC. 1999 Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13:679–685.

    Article  PubMed  CAS  Google Scholar 

  34. Pak CYC, Peters P, Hurt G, et al. 1981 Is selective therapy of recurrent nephrolithiasis possible? Am J Med 71:615–622.

    Article  PubMed  CAS  Google Scholar 

  35. Nicar M, Peterson R, Pak CYC. 1984 Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol 131:430–433.

    PubMed  CAS  Google Scholar 

  36. Odvina CV, Preminger GM, Lindberg JS, Moe OW, Pak CYC. 2003 Long-term combined treatment with thiazide and potassium citrate in nephrolithiasis does not lead to hypokalemia or hypochloremic metabolic alkalosis. Kidney Int 63:240–247.

    Article  PubMed  CAS  Google Scholar 

  37. Pak CYC, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD. 2003 Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol 169:465–469.

    Article  PubMed  CAS  Google Scholar 

  38. Borghi L, Meschi T, Guerra A, Novarini A. 1993 Randomized, prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 22:S78-S86.

    PubMed  Google Scholar 

  39. Ruml LA, Pearle MS, Pak CYC. 1997 Urolithiasis. Urol Clin North Am 24:117–133.

    Article  PubMed  CAS  Google Scholar 

  40. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CYC. 1993 Randomized double blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150:1761–1764.

    PubMed  CAS  Google Scholar 

  41. Ettinger B, Pak CYC, Citron JT, Thomas C, Adams-Huet B, Vangessel A. 1997 Potassium-Magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 153:2069–2073.

    Article  Google Scholar 

  42. Yendt ER, Cohanim M. 1985 Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria. New Engl J Med 312:953–957.

    Article  PubMed  CAS  Google Scholar 

  43. Sutton RA, Walker VR. 1994 Enteric and mild hyperoxaluria. Mineral Electrolyte Metab 20:352–360.

    CAS  Google Scholar 

  44. Sidhu H, Schmidt ME, Cornelius JG, et al. 1999 Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalo bacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 10:S334-S340.

    PubMed  CAS  Google Scholar 

  45. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. 1986 Randomized trial of allopurino in the prevention of calcium oxalate calculi. New Engl J Med 315:1386–1389.

    Article  PubMed  CAS  Google Scholar 

  46. Pak CY, Peterson R. 1986 Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med 146:863–867.

    Article  PubMed  CAS  Google Scholar 

  47. Khatchadourian J, Preminger GM, Whitson PA, Adams-Huet B, Pak CYC. 1995 Clinical and biochemical presentation of gouty diathesis: comparison of uric acid versus pure calcium stone formation. J Urol 154:1665–1669.

    Article  PubMed  CAS  Google Scholar 

  48. Pak CYC, Sakhaee K, Fuller C. 1986 Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 30:422–428.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Mineral Metabolism and Clinical Research, 5323 Harry Hines Boulevard, 75390-8885, Dallas, TX

    Mary Ann Cameron MD & Charles Y. C. Pak MD

Authors
  1. Mary Ann Cameron MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Y. C. Pak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles Y. C. Pak MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cameron, M.A., Pak, C.Y.C. Approach to the patient with recurrent neprolithiasis. Clinic Rev Bone Miner Metab 2, 279–289 (2004). https://doi.org/10.1385/BMM:2:3:279

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/BMM:2:3:279

Key Words

Search

Navigation